United Therapeutics Corporation Earnings

United Therapeutics Corporation’s revenue jumped 7.38% since last year same period to $790.2Mn in the Q4 2025. On a quarterly growth basis, United Therapeutics Corporation has generated -1.16% fall in its revenue since last 3-months.

United Therapeutics Corporation’s net profit jumped 20.91% since last year same period to $364.3Mn in the Q4 2025. On a quarterly growth basis, United Therapeutics Corporation has generated 7.56% jump in its net profits since last 3-months.

United Therapeutics Corporation’s net profit margin jumped 12.6% since last year same period to 46.1% in the Q4 2025. On a quarterly growth basis, United Therapeutics Corporation has generated 8.82% jump in its net profit margins since last 3-months.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current quarter stand at 7.44 - a 4.79% jump from last quarter’s estimates.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current year stand at 7.44.

United Therapeutics Corporation’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the United Therapeutics Corporation has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.